Neil Dunavin

University of California, San Francisco — United States

Medicine · Health Sciences

10h-index480citations66works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(18), Acute Myeloid Leukemia Research(15), Mesenchymal stem cell research(9), Multiple Myeloma Research and Treatments(8), Immune Cell Function and Interaction(8)

Publications66 total

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab
Blood·2025Open Access
Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation
Blood·2025
AML-412: Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-412 Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
Clinical Lymphoma Myeloma & Leukemia·2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Blood Neoplasia·2025· 1 citedOpen Access
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations
Blood·2024· 25 cited
IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
Blood·2024· 10 citedOpen Access
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations
Blood·2023· 42 cited
P536: A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS
HemaSphere·2023· 5 citedOpen Access
HLA-DPB1 Mismatch Permissiveness and Activating KIR Haplotypes Have Different Impact on Allogeneic Hematopoietic Cell Transplant Survival Outcomes in Acute Leukemias and Myelodysplastic Syndrome
Transplantation and Cellular Therapy·2023Open Access
Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants
Blood·2022
A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care
Clinical Lymphoma Myeloma & Leukemia·2021
WJMSC‐derived small extracellular vesicle enhance T cell suppression through PD‐L1
Journal of Extracellular Vesicles·2021· 71 citedOpen Access
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
Journal for ImmunoTherapy of Cancer·2020· 7 citedOpen Access
A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease
Stem Cell Reviews and Reports·2020· 55 citedOpen Access
A phase i study to evaluate the safety of wharton's jelly mesenchymal stem cells for the treatment of de novo high risk or steroid refractory acute Graft Versus Host Disease (aGVHD)
Cytotherapy·2020
Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings
Biology of Blood and Marrow Transplantation·2020· 9 citedOpen Access
LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing
Blood·2019· 7 cited
Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup
Blood·2019
PS1056 ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH CHROMOSOME 17 ABNORMALITIES AND LONG‐TERM OUTCOMES WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION
HemaSphere·2019Open Access
page 1 of 4Next →

Frequent Co-authors

Minoo Battiwalla(13), Siddhartha Ganguly(12), Joseph P. McGuirk(11), Sawa Ito(11), Meizhang Li(10), Sunil Abhyankar(9), Prathima Anandi(9), Andrew K. Godwin(8), Leyla Shune(8), A. John Barrett(8), Haitham Abdelhakim(7), Natasha A. Jain(7), Tara L. Lin(7), Ajoy Dias(6), Xin Tian(6), Anurag K. Singh(5), Kit Lu(5), Robert Q. Le(5), Debbie Draper(5), Mitchell W Braun(4)